Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28017584 | 0.98 | MAPT (0.43) | MAPTALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL27804563 | 0.98 | MAPT (0.43) | MAPTALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL13078874 | 0.89 | METAP2 (0.32) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16735645 | 0.81 | ABL1 (0.47) | MAPTALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL3508077 | 0.80 | METAP2 (0.45) | MAPTALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL3283468 | 0.78 | — | — | |
| SCHEMBL20848 | 0.78 | KMT2A (0.44) | MAPTALDH1A1POLBHPGDMEN1 | |
| SCHEMBL12989702 | 0.78 | AKT1 (0.48) | MAPTALDH1A1POLBHSD17B10MEN1 | |
| SCHEMBL6166437 | 0.78 | METAP2 (0.44) | APP | |
| SCHEMBL1823584 | 0.78 | METAP2 (0.44) | MAPTALDH1A1HPGDHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117946016-A | Triazole aryl polyether compound and CO2Gas-soluble viscosity reducer and thickened oil CO2Cold recovery method for improving recovery ratio | 中国石油化工股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| EP-3773552-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| WO-2019191229-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | claimed |
| EP-2872511-B1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-01-16 | — | — | EP | claimed |
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | claimed |
| EP-2858983-B1 | TNF-ALPHA MODULATING BENZIMIDAZOLES | UCB BIOPHARMA SPRL (BE) | 2018-04-18 | — | — | EP | claimed |
| US-20050143578-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2005-06-30 | — | — | US | claimed |
| EP-1434772-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040192914-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | claimed |
| EP-1434772-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2004-07-07 | — | — | EP | claimed |
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | claimed |
| EP-1274424-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | claimed |
| WO-2003031434-A1 | COMPOUNDS AND METHODS | SMITH KLINE BEECHAM CORPORATION (US) | 2003-04-17 | — | — | WO | claimed |
| EP-1274424-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-15 | — | — | EP | claimed |
| WO-2001078723-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| EP-0011719-B1 | 6-(2-HYDROXY-4-(1,2,3-TRIAZOLYL-(2))-PHENYL)-2,4-DIOXO-1,3,5-TRIMETHYL-HEXAHYDRO-S-TRIAZINES, AND THEIR PREPARATION AND USE AS INTERMEDIATES IN THE SYNTHESIS OF OPTICAL BLEACHING AGENTS | BAYER AG (DE) | 1981-09-30 | — | — | EP | claimed |
| US-4263435-A | 6-[2-Hydroxy-4-(1,2,3-triazol-2-yl)-phenyl]-2,4-dioxo-1,3,5-trimethyl-hexahydro-s-triazines and their preparation | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-21 | — | — | US | claimed |
| CN-117946016-A | Triazole aryl polyether compound and CO2Gas-soluble viscosity reducer and thickened oil CO2Cold recovery method for improving recovery ratio | 中国石油化工股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-0040357-B1 | PROCESS FOR THE PREPARATION OF V-TRIAZOLYL-(2) PHENOLS | BAYER AG (DE) | 1984-09-19 | — | — | EP | disclosed |
| EP-0040357-A1 | Process for the preparation of v-triazolyl-(2) phenols | BAYER AG (DE) | 1981-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192914-A1 | Compounds and methods | METAP2, METAP1, DNPEP | MAPT 2605/4885ALDH1A1 677/4885POLB 825/4885 |
| US-20030220371-A1 | Compounds and methods | METAP2, METAP1, DNPEP | MAPT 1864/4885ALDH1A1 1579/4885POLB 1004/4885 |
| US-20050143578-A1 | Compounds and methods | METAP2, METAP1, DNPEP | MAPT 2341/4885ALDH1A1 977/4885POLB 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.